[go: up one dir, main page]

ES2613252R1 - DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE - Google Patents

DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE Download PDF

Info

Publication number
ES2613252R1
ES2613252R1 ES201531677A ES201531677A ES2613252R1 ES 2613252 R1 ES2613252 R1 ES 2613252R1 ES 201531677 A ES201531677 A ES 201531677A ES 201531677 A ES201531677 A ES 201531677A ES 2613252 R1 ES2613252 R1 ES 2613252R1
Authority
ES
Spain
Prior art keywords
manufacture
treatment
crotonate
derivatives
renal failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES201531677A
Other languages
Spanish (es)
Other versions
ES2613252B1 (en
ES2613252A2 (en
Inventor
Alberto ORTIZ ARDÚAN
Ana SANZ BARTOLOMÉ
María Dolores SÁNCHEZ NIÑO
Olga RUIZ DE ANDRÉS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Original Assignee
Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz filed Critical Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz
Priority to ES201531677A priority Critical patent/ES2613252B1/en
Publication of ES2613252A2 publication Critical patent/ES2613252A2/en
Publication of ES2613252R1 publication Critical patent/ES2613252R1/en
Application granted granted Critical
Publication of ES2613252B1 publication Critical patent/ES2613252B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Derivados del crotonato para la fabricación de un medicamento para el tratamiento de enfermedad renal crónica y fracaso renal agudo. Uso de un compuesto seleccionado del grupo que consiste en ácido crotónico, ácido metil-crotónico, ácido etil crotónico, sales de dichos ácidos, crotonil-CoA, metil-crotonil-CoA y etil-crotonil-CoA para la fabricación de un medicamento para el tratamiento de enfermedad renal crónica y fracaso renal agudo y composición farmacéutica que comprende dichos compuestos.Crotonate derivatives for the manufacture of a drug for the treatment of chronic kidney disease and acute renal failure. Use of a compound selected from the group consisting of crotonic acid, methyl crotonic acid, ethyl crotonic acid, salts of said acids, crotonyl-CoA, methyl-crotonyl-CoA and ethyl-crotonyl-CoA for the manufacture of a medicament for treatment of chronic kidney disease and acute renal failure and pharmaceutical composition comprising said compounds.

ES201531677A 2015-11-19 2015-11-19 DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE Active ES2613252B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ES201531677A ES2613252B1 (en) 2015-11-19 2015-11-19 DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201531677A ES2613252B1 (en) 2015-11-19 2015-11-19 DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE

Publications (3)

Publication Number Publication Date
ES2613252A2 ES2613252A2 (en) 2017-05-23
ES2613252R1 true ES2613252R1 (en) 2017-11-16
ES2613252B1 ES2613252B1 (en) 2018-09-06

Family

ID=58714490

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201531677A Active ES2613252B1 (en) 2015-11-19 2015-11-19 DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE

Country Status (1)

Country Link
ES (1) ES2613252B1 (en)

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Brilli Lauren L et al. HDAC INHIBITORS IN KIDNEY DEVELOPMENT AND DISEASE. Pediatric Nephrology OCT 2013. , 30/09/2013, Vol. 28, Nº 10, Páginas 1909-1921 ISSN 0931-041X(print) ISSN 1432-198X(electronic), (DOI: doi:10.1007/s00467-012-2320-8) Todo el documento. *
Imai Naohiko et al. INHIBITION OF HISTONE DEACETYLASE ACTIVATES SIDE POPULATION CELLS IN KIDNEY AND PARTIALLY REVERSES CHRONIC RENAL INJURY. Stem Cells (Miamisburg) 2007. , 30/11/2006, Vol. 25, Nº 10, Páginas 2469-2475 ISSN 1066-5099, (DOI: doi:10.1634/stemcells.2007-0049) Todo el documento. *
Sabari B R et al. INTRACELLULAR CROTONYL-COA STIMULATES TRANSCRIPTION THROUGH P300-CATALYZED HISTONE CROTONYLATION. Molecular Cell 20150416 Cell Press usa. , 16/04/2015, Vol. 58, Nº 2, Páginas 203 - 215 ISSN 1097-2765 (print) ISSN 1097-4164 (electronic), (DOI: doi:10.1016/j.molcel.2015.02.029) Todo el documento *
Tan Minjia et al. IDENTIFICATION OF 67 HISTONE MARKS AND HISTONE LYSINE CROTONYLATION AS A NEW TYPE OF HISTONE MODIFICATION. Cell SEP 16 2011. , 31/08/2011, Vol. 146, Nº 6, Páginas 1015-1027 ISSN 0092-8674(print) ISSN 1097-4172(electronic), (DOI: doi:10.1016/j.cell.2011.08.008) Todo el documento, en especial página 1024, figura 6, gráfica C. *
Van Beneden Katrien et al. COMPARISON OF TRICHOSTATIN A AND VALPROIC ACID TREATMENT REGIMENS IN A MOUSE MODEL OF KIDNEY FIBROSIS. Toxicology and Applied Pharmacology SEP 1 2013. , 31/08/2013, Vol. 271, Nº 2, Páginas 276-284 ISSN 0041-008X(print) ISSN 1096-0333(electronic), (DOI: doi:10.1016/j.taap.2013.05.013) Todo el documento. *

Also Published As

Publication number Publication date
ES2613252B1 (en) 2018-09-06
ES2613252A2 (en) 2017-05-23

Similar Documents

Publication Publication Date Title
LT3962455T (en) NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY
BR112016015838A8 (en) heterocyclic aromatic compounds, pharmaceutical composition comprising said compounds and combination product
BR112019007576A2 (en) biphenyl sulfonamide compounds for the treatment of kidney disease or disorders
CL2014001049A1 (en) Compounds derived from substituted purine, mtor inhibitors; pharmaceutical composition; pharmaceutical combination; use for the treatment or prevention of cancer, a neurodegenerative disorder or an ophthalmological disease.
MX375068B (en) A GROUP OF COMPOUNDS USED FOR THE TREATMENT OR PREVENTION OF HYPERURICEMIA OR GOUT.
CU20140037A7 (en) DERIVATIVES OF ESTRA- 1,3,5 (10), 16- TETRAEN- 3- CARBOXIMIDE, PROCEDURES FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS THAT CONTAIN THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
DOP2015000005A (en) DERIVATIVES OF ESTRA 1,3,5 (10), 16 TETRAENE 3 SUBSTITUTES, METHODS FOR THEIR PREPARATION, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AS WELL AS THEIR USE FOR THE PREPARATION OF MEDICINES
BR112015017251A2 (en) pharmaceutical compositions comprising nitroxil donors
ECSP16084317A (en) PHARMACEUTICAL FORMULATIONS, PREPARATION PROCESSES AND METHODS OF USE
CL2013003497A1 (en) Combination pharmaceutical product in the form of dry powder for administration by means of an inhaler comprising a umeclidinium salt of a defined group and 100 mcg / dose of fluticasone furoate, without other additional assets; use for the treatment of inflammatory or respiratory diseases.
IL281353A (en) A pharmaceutical preparation for the prevention or treatment of fatty liver disease not due to alcohol consumption, containing GPR119 ligand as an active ingredient
EP3481465A4 (en) DRUG DELIVERY ASSEMBLY FOR CARTRIDGE MEDICINES
EA201890532A1 (en) NEW ANNELED BENZAMIDES
CY1124527T1 (en) PI3K/MTOR INHIBITOR PREPARATION FOR INTRAVENOUS ADMINISTRATION
BR112018006206A2 (en) composition, use of a combination, pharmaceutical fixed dosage form, fixed dosage combination, packaging, and use of a fixed dose combination
RU2018126158A (en) APPLICATION OF TRIACETHYL-3-HYDROXYPHENYLENADENOSINE FOR THE PRODUCTION OF A PHARMACEUTICAL MEDICINE FOR THE PREVENTION OR TREATMENT OF A NON-ALCOHOLIC LIVER LIVER DISEASE DISEASE
WO2016006975A3 (en) Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof
WO2016006974A3 (en) Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof
CO2018014217A2 (en) Pharmaceutical compositions comprising safinamide
IL283721A (en) Formulation for administering a drug through the large intestine
CL2013002325A1 (en) Compounds derived from 4-amino-2-butenamides, cathepsin c inhibitors; pharmaceutical composition that includes them; preparation procedure of the pharmaceutical composition; use of the compound in the treatment of chronic obstructive pulmonary disease.
ES2613252R1 (en) DERIVATIVES OF CROTONATE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF CHRONIC RENAL DISEASE AND ACUTE RENAL FAILURE
ECSP17008187A (en) PHARMACEUTICAL DOSAGE FORMS
WO2016092560A3 (en) Dual release bilayer tablets comprising metformin
ES2571441A1 (en) Use of molecules that reduce lipocalin-2 levels for the manufacture of a drug for the treatment of abdominal aortic aneurysm (AAA)

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2613252

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20180906